Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

-cell malignancies, including several NHL subtypes, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). This study was an open-label, nonrandomized, multicenter study consisting of 2 parts: dose escalation in patients with DLBCL, MCL and FL (Part 1) and dose expansion only in DLBCL patients (Part 2). The primary objective of this phase 1B study in 33 patients was to determine the recommended phase 2 dose and dose-limiting toxicities of ibrutinib in combination with R-CHOP. Secondary objectives were to evaluate safety, ORR and pharmacokinetics. The results below focus on the 24 DLBCL patients across Parts 1 and 2 of the study.

Across Parts 1 and 2 (n=24), the most common all-grade treatment-emergent AEs (> 25%) were neutropenia (70.8%), nausea (66.7%), vomiting (66.7%), thrombocytopenia (58.3%), fatigue (50%), constipation (41.7%), anemia (41.7%), and diarrhea (33.3%). The most common Grade 3 or higher treatment-emergent AEs were neutropenia (66.7%), thrombocytopenia (16.7%), febrile neutropenia (16.7%), anemia (12.5%) and hypotension (8.3%).

The ORR for all evaluable patients across Parts 1 and 2 was 91.7%, with 83.3% of patients achieving a CR, and 8.3% achieving a PR.

Pre-Clinical and Non-Clinical Presentation Highlights

During the ASH meetings this year a total of 33 pre-clinical and non-clinical presentations were presented, 7 of these were oral and 26 poster presentations. The data presented provides further insights into ibrutinib including: 1) the potential reconstitution of the immune system in CLL patients 2) valuable findings of mechanism of action of ibrutinib 3) the apoptotic effect (cell death) of ibrutinib in both the tissue and blood for CLL cells and 4) many models illustrating combinations with many other therapies. Below are a select, few abstracts:

Poster Abstract #4182: In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectivel
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84p6xc/investigation ) ... on China,s Bromhexine Market, 2010-2019" report to their ... of respiratory disease keeps growing and so does the ... of vasicine, is a mucolytic agent used in the ... or excessive mucus. It can make the phlegm thinner ...
(Date:9/3/2015)... , Sept. 3, 2015  CVS Health Corporation ... Merlo , the company,s president and chief executive officer, ... chief financial officer, will be speaking to investors at ... 17, 2015. They are scheduled to speak at approximately ... the presentation will be broadcast simultaneously through the Investor ...
(Date:9/3/2015)... 03, 2015 Research and ... the "Investigation Report on China Oxiracetam Market, 2010-2019" ... derivative of pyrrolidone, was first synthesized by ISF in ... and injection entered the Italian market respectively in 1987 ... China , annual sales rising from ...
Breaking Medicine Technology:China Bromhexine Market Report 2015-2019 2Investigation Report on China's Oxiracetam Market, 2010-2019 2
(Date:9/3/2015)... ... September 03, 2015 , ... Topical BioMedics, Inc., ... destination of his six-month, 10,000 mile journey from Santiago, Chile to Times Square ... calls the “Connecting Las Americas” project—Max crossed six countries in 168 days on ...
(Date:9/3/2015)... ... September 03, 2015 , ... Real Time Pain Relief ... professional bull rider David Mason has signed an official endorsement deal with the company. ... of six and his first bull at 15. He is an Australian bull riding ...
(Date:9/3/2015)... PEACHTREE CITY, GA (PRWEB) , ... September 03, ... ... does not cover the cost of graduated compression garments. However, graduated compression garments ... management. , Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by ...
(Date:9/3/2015)... ... September 03, 2015 , ... The first part of ... allegations made by IVC filter lawsuits filed against Bard.** These lawsuits, filed ... a Bard IVC filter broke or failed, have recently been consolidated for pretrial proceedings ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... comprehensive eating disorder treatment for adults and adolescents struggling with anorexia, bulimia, ... has joined the medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu ...
Breaking Medicine News(10 mins):Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 2Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 3Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 4Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 5Health News:Topical BioMedics Announces Visit from Max Wohlgemuth Kitslaar, Ending his Six-Month, 10,000 Mile Journey from Chile to New York on a 1976 Moto Guzzi Motorcycle 6Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 2Health News:Bard IVC Lawsuit Allegations Reach National Prime Time News 3Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3
... ... 100 Attorneys in New England - Result of Peer-review Process , , ... Boston, MA (PRWEB) December 9, 2009 -- Boston medical malpractice ... named among the "Top 100" lawyers in New England for 2009 as listed by Super Lawyers ...
... Beverly ... Face Institute, to The Big Apple. A world famous rhinoplasty and facelift surgeon as featured ... East Coast and West Coast patients. , ... Rancho Cucamonga, CA (PRWEB) December 9, 2009 -- Southern California facial plastic ...
... , March of Dimes Polls Moms On Their ... 9 Moms worry. Even before they become moms. From the minute they ... the birth, moms worry. , Will my baby be healthy? Will I ... I eat? , The March of Dimes polled about 1,200 moms to ...
... Dec. 8 Beckman Coulter, Inc. (NYSE: BEC ... simplify, automate, and innovate complex biomedical tests, will host its ... Thursday, December 17, 2009, from 2:30 p.m. to 5:00 p.m. ... Charlie Slacik, chief financial officer, and other corporate executives will ...
... ... , ... (PRWEB) December 8, 2009 -- Many parents dread the holiday season as they struggle ... parents worried and isolated. Rather than celebrating the holiday season, parents are concerned ...
... Healthcare consultant partners with Laguna Honda Hospital ... Health , SAN FRANCISCO, Dec. 8 ... on a new 11-month contract with The City and County ... model of care and organizational effectiveness development program for the ...
Cached Medicine News:Health News:Andrew C. Meyer, Jr. and Robert M. Higgins Named Top 100 New England Super Lawyers 2Health News:Dr. 90210 Rhinoplasty Specialist Now Accommodates Both the East and West Coast 2Health News:Sushi & Breastfeeding Join Birth Defects & Preterm Birth as Leading Concerns of Moms 2Health News:Beckman Coulter to Host Annual Business Review 2Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 3
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique to be used in left hand. Round knurled handle....
Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
Small bulbous tip with flat sides. Flat serrated handle with polished finish. Overall length: 5.1 inches....
Medicine Products: